Regarding solid tumors, imgatuzumab, one of the most advanced glyco-engineered antibody, showed promising results in epidermal growth factor receptor (EGFR)-positive solid tumors [21], in head and neck squamous cell carcinoma and in colorectal cancer showing complete and partial response in Phase I and II studies [22,23], especially with tumors highly infiltrated by immune cells at baseline. Here, EGFR is linked to colorectal cancer.